Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss	$ (24,620)	$ (6,169)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	1,506	308
Depreciation	8	3
Non-cash acquired in-process research and development	10,502	0
Gain on note extinguishment	(3,672)	0
Non-cash interest on convertible notes	492	252
Non-cash interest on convertible notes - related party	51	42
Non-cash discount amortization on convertible notes	873	1,014
Non-cash discount amortization on convertible notes - related party	71	101
Fair value change in derivative and warrant liabilities	1,486	499
Non-cash interest attributed to Series A warrant issuance	4,671	0
Issuance costs attributed to Series A warrants	689	0
Change in assets and liabilities:
Prepaid expenses and other assets	(906)	58
Accounts payable	792	(168)
Accrued and other liabilities	1,260	467
Net cash used in operating activities	(6,797)	(3,593)
Investing activities
Cash acquired in connection with asset acquisition	2,014	0
Transaction costs in connection with asset acquisition	(1,475)	0
Purchases of property and equipment	0	(25)
Net cash provided by (used in) investing activities	539	(25)
Financing activities
Proceeds from pre-merger financing	21,150	0
Proceeds from issuance of convertible notes	2,197	4,383
Proceeds from issuance of convertible notes - related party	0	323
Issuance costs attributed to pre-merger financing	(1,769)	0
Issuance costs attributed to convertible notes	(10)	(2)
Settlement of Rexahn warrants	(506)	0
Exercise of stock options	58	0
Net cash provided by financing activities	21,120	4,704
Net increase in cash and cash equivalents	14,862	1,086
Cash and cash equivalents at beginning of period	1,537	451
Cash and cash equivalents at end of period	16,399	1,537
Supplemental disclosure of cash flow information:
Cash paid for income taxes	0	0
Cash paid for interest	0	0
Supplemental non-cash financing transactions:
Non-cash conversion of convertible notes to common stock	9,365	0
Common stock and warrants issued in connection with the asset acquisition	8,883	0
Unpaid transaction costs in connection with asset acquisition	100	0
Net assets assumed in connection with asset acquisition	68	0
Bifurcation and modification of premium conversion derivative related to convertible notes	831	1,910
Unpaid deferred offering costs	0	76
Proceeds receivable from convertible note issuance	$ 0	$ 125